We report three acute myelogenous leukemia (AML) patients who developed intracerebral granulocytic sarcomas (GS) and were successfully treated with allogeneic BMT (allo-BMT). The diagnosis of one patient was AML M2 with myelofibrosis, and the other two patients were AML M4 with eosinophilia (AML M4 Eo), according to the FAB classification. Two patients first experienced a relapse in the brain that resulted in the formation of GS, followed by a relapse in the bone marrow. The remaining patient developed an optic nerve GS after suffering a bone marrow relapse. All three patients received irradiation for the GS and systemic chemotherapy before the allo-BMT. TBI was used for conditioning, and GVHD prophylaxis was with cyclosporine (CsA) and short-term MTX in all three cases. These patients are currently 9 to 37 months post-BMT without relapse. Thus, our experience suggests that allo-BMT is an effective treatment for AML patients with existing or pre-existing intracerebral GS. Keywords: AML; intracerebral granulocytic sarcoma; allogeneic BMT Granulocytic sarcoma (GS) is a rare extramedullary tumor composed of myeloblasts and other granulocytic precursors. The subgroups of AML, AML M2 with t(8;21)(q22;q22) 1 and AML with CD56-positive leukemic cells 2 tend to develop GS. Granulocytic sarcoma can occur at any location in the body in patients with adult AML, but it rarely does in the CNS.
Granulocytic sarcoma (GS) is a rare extramedullary tumor composed of myeloblasts and other granulocytic precursors. The subgroups of AML, AML M2 with t(8;21)(q22;q22) 1 and AML with CD56-positive leukemic cells 2 tend to develop GS. Granulocytic sarcoma can occur at any location in the body in patients with adult AML, but it rarely does in the CNS. 3 Although such patients receive intracerebral treatment, whole brain irradiation, and/or systemic chemotherapy, they have low complete remission (CR) rates and short overall survivals. Hence, in some cases, aggressive therapy such as bone marrow transplantation is recommended.
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Case reports

Case 1
A 46-year-old male was diagnosed with AML M2, with myelofibrosis. At diagnosis, cytogenetic analysis showed 46, XY, 9q−. Flow cytometric analysis was compatible with AML, but CD56 was not examined. He achieved CR with enocitabine (BHAC) 2200 mg/m 2 i.v., daunorubicin (DNR) 240 mg/m 2 i.v. and mercaptopurine (6-MP) 700 mg/m 2 p.o. (total dose). Eleven months later, however, he complained of nausea, vomiting, and headache. A brain CT revealed the presence of enhanced multiple mass lesions. There was no indication of a bone marrow relapse, and a brain biopsy was not performed. A CNS relapse was diagnosed resulting in the formation of GS, and whole brain irradiation was given to 40 Gy. A brain CT subsequently detected no mass lesion. Notwithstanding, this patient suffered a bone marrow relapse 6 months later. He then received induction therapy with mitoxantrone (MIT) 30 mg/m 2 i.v., cytosine arabinoside (ara-C) 700 mg/m 2 i.v. and etoposide (VP-16) 560 mg/m 2 i.v., and the myeloblasts decreased to 7% of the bone marrow nucleated cells. Following this chemotherapy, he complained of a gait disturbance, and a brain MRI revealed mass lesions in the right frontal and left occipital lobes. Whole brain irradiation (20 Gy) and partial brain irradiation limited to the right frontal and occipital lobes (10 Gy) was carried out. His condition improved, but a lumbar puncture revealed 700/l mononuclear cells which were positive for peroxidase staining. He received intrathecal therapy with methotrexate (MTX 15 mg), ara-C (40 mg), and prednisolone (PSL 10 mg). Reinduction therapy with BHAC 1225 mg/m 2 i.v., VP-16 500 mg/m 2 i.v., vincristine (VCR) 0.8 mg/m 2 i.v. and vinblastine (VLB) 6 mg/m 2 i.v. was also given. Although the mononuclear cells in the CSF diminished, his gait disturbance persisted. He received an allo-BMT from his HLA-identical brother prior to hematological recovery. Conditioning included VP-16 (80 mg/kg) and fractionated TBI (12 Gy), excluding the brain. CsA (3 mg/kg i.v.) from day −1 and short-term MTX were used to prevent GVHD. Hematopoiesis was completely restored without the occurrence of acute GVHD. To induce a graft-versus-leukemia (GVL) effect, CsA was discontinued on day 35, and donor leukocyte infusions (DLI) were administered on day 53 (mononuclear cells: 1.8 × 10 8 /kg) and on day 70 (mononuclear cells: 2.5 × 10 8 /kg). On day 80, acute GVHD limited to the skin (grade 1) appeared, but it was effectively controlled by CsA. His gait disturbance gradually disappeared and, after the allo-BMT, a brain MRI showed no mass lesions but did reveal slight leukodystrophy. A lumbar puncture performed on day 98 confirmed that there were no mononuclear cells in the CSF. He is currently 37 months post-BMT with no indication of relapse or GVHD.
Case 2
A 31-year-old male was diagnosed with AML M4 Eo. At diagnosis, the cytogenetic analysis showed 47, XY, inv(16), +22. Flow cytometric analysis was compatible with AML, but CD56 was not examined. He entered CR with idarubicin (IDR) 36 mg/m 2 i.v. and ara-C 700 mg/m 2 i.v. Eighteen months later, he was readmitted to hospital because of a bone marrow relapse and right hemianopia. A lumbar puncture revealed 190/l mononuclear cells which were positive for peroxidase. Brain CT revealed a mass on the right optic nerve, and we concluded from this that he had suffered a relapse in both the bone marrow and the CNS, resulting in the formation of GS. Intensive chemotherapy with ara-C 24 g/m 2 i.v., intrathecal MTX, ara-C, and PSL, and irradiation to the right optic nerve (40 Gy) were given. He achieved CR and his visual disturbance disappeared. Nevertheless, he suffered a second bone marrow relapse 3 months later and received an allo-BMT from his father donor whose HLA type was a one locus mismatch (A locus). Conditioning included IDR (10 mg/m 2 ), TBI (12 Gy), and CY (120 mg/kg). CsA (3 mg/kg i.v.) from day −1 and shortterm MTX were used as GVHD prophylaxis. His hematopoiesis was completely restored with no indication of acute GVHD. CsA was tapered to induce a GVL effect, which caused the onset of acute GVHD that was limited to the skin (grade 2). It was controlled by increasing the dosage of CsA. A brain MRI showed no mass on the right optic nerve at discharge. He is currently 18 months post-BMT with no evidence of relapse or GVHD.
Case 3
A 49-year-old female was diagnosed with AML M4 Eo. Cytogenetic analysis showed 46, XX, inv(16). Flow cytometric analysis was compatible with AML, but CD56 was not examined. She entered CR with IDR 36 mg/m 2 i.v. and ara-C 700 mg/m 2 i.v. and was discharged, but was readmitted to hospital 10 months later because of headache and left hemianopia. An MRI showed multiple masses in the brain (Figure 1 ), and symptoms of raised intracranial pressure such as nausea, vomiting, and papillary stasis were present precluding CSF examination. Bone marrow examination, however, showed no evidence of relapse. We concluded that she had suffered a CNS relapse resulting in the formation of intracerebral GS. Whole brain irradiation was given (50 Gy). A subsequent lumbar puncture revealed 148/l mononuclear cells. She later suffered a bone marrow relapse. Hematological CR was achieved with mitoxantrone (MIT) 21 mg/m 2 i.v. and ara-C 5 g/m 2 i.v., and the mononuclear cells in the CSF disappeared with intrathecal MTX, ara-C, and PSL. However, an MRI revealed the presence of an enhanced mass in the left occipital lobe (Figure 2) , and we could not determine if it was a GS or glioma. She underwent radiotherapy (limited to the mass) (40 Gy), and i.v. Unfortunately, the mass was unresponsive (Figure 3) , so she received an allo-BMT from a sister whose HLA type was a one locus mismatch (B locus). Conditioning included TBI (12 Gy) and CY (120 mg/kg). CsA (3 mg/kg i.v.) from day −1 and short-term MTX were used as GVHD prophylaxis. Hematopoiesis was completely restored, but onset of acute GVHD limited to the skin (grade 2) occurred. This was controlled with steroid pulse therapy. A lumbar puncture on day 174 revealed the continued presence of mononuclear cells in the CSF (35/l). RT-PCR analysis confirmed that these cells were free of CBFbeta-MYH11 mRNA, which had been previously detected in the marrow. A brain MRI showed no mass but did reveal a slight leukodystrophy (Figure 4) . We concluded that there were no leukemic cells in the CSF and she is currently 9 months without relapse with extensive chronic GVHD.
Discussion
Granulocytic sarcoma rarely occurs in AML, MDS, and CML patients. Some patients, however, do experience a greater incidence of GS, including AML M2 with t(8;21)(q22;q22), 1 and AML with CD56-positive leukemia cells. 2 In many cases, GS appears adjacent to the bony or neural structures, and it can develop either before or after the onset of leukemia, and at any time during the clinical course. 4, 5 Meningeal leukemia is common while intracerebral GS is rare. Some AML patients, particularly those with CD56-positive cells, develop GS in the brain. 2 Although a treatment approach for GS has not been fully established, it has been shown that local treatments such as radiotherapy and intrathecal therapy are ineffective even when there is no evidence of bone marrow disease. 3 The main reason for this is that most patients suffer a bone mar- row relapse after local therapy. The very few successfully treated patients with intracerebral GS, received a combination of intrathecal therapy, whole brain irradiation, and systemic chemotherapy. 6, 7 It is important to understand that radiotherapy and/or intrathecal therapy may cause leukoencephalopathy in patients with CNS disease, closely related to the following: (1) high cumulative doses of intrathecal MTX; (2) combined intrathecal chemotherapy and whole brain irradiation; (3) high doses of radiation; and (4) the method of radiotherapy delivery (fractionated or not). 8, 9 Although the efficacy of allo-BMT for AML patients with CNS disease has not been established, it has been reported that previous meningeal leukemia does not correlate with an increased risk of CNS relapse in patients who have received an allo-BMT for AML. 10 To our knowledge this report may be the first concerning the use of allo-BMT for the treatment of AML in patients with existing or preexisting intracerebral GS.
Recently, it has been shown that allo-BMT is not only effective against malignancies by virtue at the conditioning but also because of the graft-versus-leukemia (GVL) effect. In addition, it has been reported that the GVL effect is dependent upon GVHD in the HLA-identical sibling BMT. 11 The GVL effect in HLA mismatched cases, such as cases 2 and 3 presented here, has yet to be established. In our view, patients who receive HLA mismatched grafts have a lower risk of relapse because they have a higher frequency of GVHD. Another important point is whether or not the GVL effect exists in extramedullary lesions, especially in the CNS. Recent studies have revealed that the GVL effector cells are CD8-and/or CD4-positive T cells which originate in the donor. Therefore, to obtain a GVL effect in the CNS, it would be necessary for these effector cells to enter the CNS and make contact with the leukemic cells. Concerning the presence of leukocytes in the CNS, the following has been previously reported: (1) Figure 4 Case 3: gadolinium-enhanced MRI after an allo-BMT. It showed no mass lesion but did reveal a slight leukodystrophy.
unlike alveolar macrophages and interstitial mucosal mononuclear cells, leukocytes in the CNS show complete donor typing in the early phase when complete donor type hematopoiesis is observed; 12 (2) although leukocytes in the CSF are minimal, and turnover is very slow under normal conditions, they increase after TBI because of damage to the blood-brain barrier. 13, 14 These previous reports may help to confirm the existence of a GVL effect in the CNS. In any event, conclusive evidence for the existence of a GVL effect in the CNS is considered the central problem. If a GVL effect in the CNS does indeed exist, or if it can be induced, we strongly recommend allo-BMT treatment for patients with CNS leukemia.
